Payment overview · 2025
General Payments
$32.13
2 reported records · 2 companies
Healthcare provider profile · identity verified
David Yorio, D.O
Allopathic & Osteopathic Physicians|Family Medicine · WAYNE, NJ · NPI 1487759171
Verified facts
What the public records show
CMS Open Payments records show David Yorio, D.O received $32.13 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 50.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.14 | 50.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.99 | 49.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $32.13 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 440 | 79 |
| Alprazolam | Alprazolam | 281 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 222 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 218 | 53 |
| Gabapentin | Gabapentin | 202 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 46 |
| Furosemide | Furosemide | 182 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 36 |
| Methylprednisolone | Methylprednisolone | 168 | 117 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 166 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 165 | 43 |
| Metformin Hcl | Metformin Hcl | 154 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 151 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 28 |
| Simvastatin | Simvastatin | 138 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 35 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 129 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 127 | 43 |
| Losartan Potassium | Losartan Potassium | 125 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 33 |
| Ozempic | Semaglutide | 122 | 23 |
| Montelukast Sodium | Montelukast Sodium | 116 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 24 |
| Azithromycin | Azithromycin | 93 | 66 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 27 |
| Cefuroxime | Cefuroxime Axetil | 87 | 65 |
| Mounjaro | Tirzepatide | 82 | 13 |
| Naproxen | Naproxen | 81 | 21 |
| Trazodone Hcl | Trazodone Hcl | 81 | 25 |
| Ibuprofen | Ibuprofen | 75 | 19 |
| Omeprazole | Omeprazole | 73 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 45 |
| Eliquis | Apixaban | 72 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 20 |
| Donepezil Hcl | Donepezil Hcl | 66 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | suppressed |
| Famotidine | Famotidine | 63 | 21 |
| Mirtazapine | Mirtazapine | 63 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 14 |
| Carvedilol | Carvedilol | 59 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 14 |
| Clonidine Hcl | Clonidine Hcl | 55 | suppressed |
| Prednisone | Prednisone | 55 | 12 |
| Sertraline Hcl | Sertraline Hcl | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 51 | 12 |
| Potassium Chloride | Potassium Chloride | 51 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 11 |
| Finasteride | Finasteride | 49 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 48 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Ketoconazole | Ketoconazole | 45 | 13 |
| Linzess | Linaclotide | 45 | suppressed |
| Lisinopril | Lisinopril | 45 | 15 |
| Allopurinol | Allopurinol | 44 | 12 |
| Lorazepam | Lorazepam | 44 | 11 |
| Latanoprost | Latanoprost | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 22 |
| Clonazepam | Clonazepam | 36 | 12 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Meloxicam | Meloxicam | 34 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 19 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Epinephrine | Epinephrine | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Atenolol | Atenolol | 29 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Ofloxacin | Ofloxacin | 22 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 11 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Tobramycin | Tobramycin | 15 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Dexilant | Dexlansoprazole | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Jublia | Efinaconazole | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32.13 · 2 records | AstraZeneca Pharmaceuticals LP | BREZTRI, PAXLOVID | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error